Celgene - 47 Year Dividend Yield History | CELG

Historical dividend payout and yield for Celgene (CELG) since 1971. The current TTM dividend payout for Celgene (CELG) as of December 10, 2018 is $0.00. The current dividend yield for Celgene as of December 10, 2018 is 0.00%.
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $49.004B $13.003B
Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Their portfolio of commercial products include REVLIMID, VIDAZA, THALOMID, POMALYST/IMNOVID, ABRAXANE, OTEZLA, ISTODAX and IDHIFA. The drug candidates in their pipeline are at various stages of preclinical and clinical development. These candidates include their IMiDs compounds, which are a proprietary class of compounds that have certain immunomodulatory and other biologically important properties in addition to their leading oral anti-inflammatory agents and cellular therapies. They believe their commercial stage products and the depth of their product pipeline, provide the catalysts for future growth.
Stock Name Country Market Cap PE Ratio
Amgen (AMGN) United States $121.989B 13.79
Gilead Sciences (GILD) United States $88.160B 10.61
Bio-Techne Corp (TECH) United States $5.900B 39.85